Barinthus Biotherapeutics (BRNS)
1.03
0.05 (5.63%)
At close: Jan 14, 2025, 3:58 PM
0.95
-8.00%
After-hours Jan 14, 2025, 03:59 PM EST
undefined% (undefined)
| Bid | 0.91 |
| Market Cap | 40.72M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.49 |
| PE Ratio (ttm) | -0.69 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.3 |
| Volume | 22,867 |
| Avg. Volume (20D) | 51,932 |
| Open | 1.00 |
| Previous Close | 0.98 |
| Day's Range | 0.91 - 1.12 |
| 52-Week Range | 0.80 - 4.16 |
| Beta | undefined |
About BRNS
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, ...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 30, 2021
Employees 130
Stock Exchange NASDAQ
Ticker Symbol BRNS
Website https://www.barinthusbio.com
Analyst Forecast
According to 2 analyst ratings, the average rating for BRNS stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 191.29% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 months ago ·
Source
+10.45%
Barinthus Biotherapeutics shares are trading highe...
Unlock content with
Pro Subscription